

## ORGANIZING COMMITTEE

### Catarina Brito

Animal Cell Technology Unit, IBET/ITQB-UNL  
Apartado 12  
2780-901 Oeiras  
Portugal  
Tel.: +351 21 4469434  
email: anabrito@ibet.pt

### Heinz Ruffner

Novartis  
CH-4056 Basel  
WSJ-Fabrikstrasse 22-4.025.1  
Switzerland  
Tel +41 79 863 5219  
email: heinz.ruffner@novartis.com

### Hansjörg Hauser

Helmholtz Centre for Infection Research (HZI)  
Inhoffenstrasse 7  
38124 Braunschweig  
Germany  
Tel.: +49 531 6181 5000  
email: hha@helmholtz-hzi.de

## FEE

EUR 150.- for academic participants and EUR 250.- for industry participants.

The fee covers course registration and e-course book.

## APPLICATION

A **limited number of grants**, covering the course fee (not travel cost), are provided by ESACT. Applicants to the grants should indicate it in the course application, together with a motivation statement. Priority will be given to young PhD students from academia.

**All applications should be sent before September 1<sup>st</sup>. Accepted applicants will be notified by September 12<sup>th</sup> and should register and complete payment by September 30<sup>th</sup>, 2021 at the latest**

## AIM

This is an introductory course to drug development, providing an overview of the field, offering basic aspects and pharmaceutical application. It will be of to those starting research or development activity in drug development, both from academia and companies (lab managers, scientists, post-docs, PhD students and engineers). It is also of interest for those wishing an update of the state-of-the-art of drug development in a short course.

## COURSE OUTLINE

The course is planned in an intensive three-day schedule with a number of participants limited to 30 in order to facilitate the interaction among them and with the lecturers. Lecturers will stay for the entire course duration.

The course will touch the following aspects in blocks:

- 1 **Drug discovery overview**
- 2 **Cellular assays for target identification & validation**
- 3 **Engineering cells for drug screening and validation**
- 4 **Translatable models: primary cells, stem cells, organoids**
- 5 **Biochemical assays**
- 6 **Assays bridging in vitro and in vivo**
- 7 **Animal models including PK/PD and efficacy**
- 8 **Biomarkers**

The program has slots dedicated to the preparation and presentation of case studies by participants and provides time for discussion with the lecturers.

## LECTURERS

Confirmed lecturers include Catarina Brito (IBET, Portugal), Hansjörg Hauser (HZI, Germany), Nikunj Somia, University of Minnesota, USA), Carsten Pieck (Merck, Germany), Heinz Ruffner (Novartis, Switzerland), Wolfgang Sommergruber (University of Applied Sciences, Austria).

Other information can be found at [www.esact.org](http://www.esact.org).




# DRUG DEVELOPMENT COURSE 2021

FIFTH EDITION

October 12<sup>th</sup> - 15<sup>th</sup>, 2021

Llafranc, Costa Brava / Spain



Photos: [www.ibet.pt](http://www.ibet.pt)

With the contribution of:



ACTIP

## PROGRAMME

	Tuesday 12 <sup>th</sup> Oct	Wednesday 13 <sup>th</sup> Oct	Thursday 14 <sup>th</sup> Oct	Friday 15 <sup>th</sup> Oct
13:00 - 13:50	Introduction to the Course & Presentation of Participants	Cellular assays for target identification and validation <i>Heinz Ruffner</i>	Biochemical assays <i>Carsten Pieck</i>	Animal models, including PK/PD and efficacy <i>Hansjörg Hauser</i>
break				
14h00 - 14h50	The Drug Discovery Process <i>Heinz Ruffner</i>	Translatable models: primary cells, stem cells, organoids <i>Catarina Brito</i>	Biochemical assays <i>Wolfgang Sommergruber</i>	Biomarkers and surrogate endpoints <i>Wolfgang Sommergruber</i>
break				
15h00 - 15h50	Drug Discovery: General Considerations <i>Carsten Pieck</i>	Translatable models: primary cells, stem cells, organoids <i>Heinz Ruffner</i>	Assays bridging in vitro and in vivo <i>Carsten Pieck</i>	Gene therapy <i>To be determined</i>
break				
16h00 - 16h50	Engineering cells for drug screening and validation <i>Hansjörg Hauser</i>	Translatable models: primary cells, stem cells, organoids <i>Wolfgang Sommergruber</i>	Assays bridging in vitro and in vivo <i>Catarina Brito</i>	Wrap-up session and Course closing

Course will be held live, all times are Central European Summer Time (CEST).

## Drug Development Course 2018 3<sup>rd</sup> edition



Llafranc, Costa Brava / Spain

## REGISTRATION and CONTACT

**Registration / Payment deadline is August 18<sup>th</sup>, 2021**  
Updated information will be available at ESACT website  
[www.esact.org](http://www.esact.org)

**Contact for registration:**  
ESACT office - Birgit Marckhgott  
E-mail: [office@esact.org](mailto:office@esact.org)